Co-encapsulation of combretastatin-A4 phosphate and doxorubicin in polymersomes for synergistic therapy of nasopharyngeal epidermal carcinoma

Journal of Biomedical Nanotechnology

Volumn 11, Issue 6, 2015, Pages 997-1006

  Zhu, Jinfang ^b,c   Xu, Xiaoping ^d   Hu, Mengying ^b   Qiu, Liyan ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c XINJIANG AGRICULTURAL UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Antiangiogenic drug; Cancer therapy; Combretastatin A4 phosphate; Doxorubicin; Polymersomes

Indexed keywords

BIODEGRADABLE POLYMERS; BLOCK COPOLYMERS; CELL PROLIFERATION; DISEASES; MOTION PICTURE EXPERTS GROUP STANDARDS; ONCOLOGY; ORGANIC SOLVENTS; POLYETHYLENE GLYCOLS; TUMORS;

ANTIANGIOGENIC; BIODEGRADABLE POLYMERSOMES; CANCER THERAPY; DOXORUBICIN; METHOXYPOLYETHYLENE GLYCOL; POLYMERSOMES; PROLIFERATION INHIBITION; SOLVENT EVAPORATION METHOD;

DRUG THERAPY;

COMBRETASTATIN A4 PHOSPHATE; COPOLYMER; DOXORUBICIN; MACROGOL; ANTINEOPLASTIC AGENT; DRUG CARRIER; DRUG COMBINATION; NANOCAPSULE; POLYMER; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CARCINOMA CELL; CELL DISRUPTION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SOLUBILITY; ENCAPSULATION; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NANOENCAPSULATION; NASOPHARYNGEAL EPIDERMAL CARCINOMA; NASOPHARYNX CARCINOMA; NONHUMAN; PH; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ULTRAVIOLET SPECTROPHOTOMETRY; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG COMBINATION; DRUG FORMULATION; DRUG SCREENING; METABOLISM; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG CARRIERS; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOCAPSULES; NASOPHARYNGEAL NEOPLASMS; POLYMERS; STILBENES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918536439     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2010     Document Type: Article

References (46)

1. P. A. Burke and S. J. Denardo, Antiangiogenic agents and their promising potential in combined therapy. Crit. Rev. Oncol. Hematol. 39, 155 (2001).
2. J. Folkman, Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182 (1971).
3. J. Folkman, Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 175, 409 (1972).
4. B. A. Salmon and D. W. Siemann, Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int. J. Radiat. Oncol. Biol. Phys. 68, 211 (2007).
5. G. Pettit, S. Singh, E. Hamel, C. M. Lin, D. Alberts, and D. Garcia- Kendal, Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45, 209 (1989).
6. V. E. Prise, D. J. Honess, M. R. Stratford, J. Wilson, and G. M. Tozer, The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21, 717 (2002).
7. C. Cenciarelli, C. Tanzarella, I. Vitale, C. Pisano, P. Crateri, S. Meschini, G. Arancia, and A. Antoccia, The tubulindepolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460 Apoptosis 13, 659 (2008).
8. I. Petit, M. A. Karajannis, L. Vincent, L. Young, J. Butler, A. T. Hooper, K. Shido, H. Steller, D. J. Chaplin, and E. Feldman, The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrialdependent cell death. Blood 111, 1951 (2008).
9. H. Wang, Y. Zhao, Y. Wu, Y. L. Hu, K. Nan, G. Nie, and H. Chen, Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32, 8281 (2011).
10. N. Wiradharma, Y. W. Tong, and Y. Y. Yang, Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 30, 3100 (2009).
11. W. Xiao, X. Chen, L. Yang, Y. Mao, Y. Wei, and L. Chen, Codelivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int. J. Pharm. 393, 120 (2010).
12. A. L. Lee, Y. Wang, H. Y. Cheng, S. Pervaiz, and Y. Y. Yang, The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30, 919 (2009).
13. F. Ahmed, R. I. Pakunlu, G. Srinivas, A. Brannan, F. Bates, M. L. Klein, T. Minko, and D. E. Discher, Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol. Pharma. 3, 340 (2006).
14. F. Meng, Z. Zhong, and J. Feijen, Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 10, 197 (2009).
15. W. Chen, F. Meng, R. Cheng, and Z. Zhong, pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: A comparative study with micelles. J. Control. Release 142, 40 (2010).
16. F. Ahmed and D. E. Discher, Self-porating polymersomes of PEG- PLA and PEG-PCL: Hydrolysis-triggered controlled release vesicles. J. Control. Release 96, 37 (2004).
17. F. Meng and Z. Zhong, Polymersomes spanning from nano-to microscales: Advanced vehicles for controlled drug delivery and robust vesicles for virus and cell mimicking. J. Phys. Chem. Lett. 2, 1533 (2011).
18. D. E. Discher and F. Ahmed, Polymersomes. Annu. Rev. Biomed. Eng. 8, 323 (2006).
19. D. E. Discher, V. Ortiz, G. Srinivas, M. L. Klein, Y. Kim, D. Christian, S. Cai, P. Photos, and F. Ahmed, Emerging applications of polymersomes in delivery: from molecular dynamics to shrinkage of tumors. Prog. Polym. Sci. 32, 838 (2007).
20. J. S. Lee and J. Feijen, Biodegradable polymersomes as carriers and release systems for paclitaxel using Oregon Green® 488 labeled paclitaxel as a model compound. J. Control. Release 158, 312 (2012).
21. H. R. Marsden, L. Gabrielli, and A. Kros, Rapid preparation of polymersomes by a water addition/solvent evaporation method. Polym. Chem. 1, 1512 (2010).
22. J. S. Katz, D. H. Levine, K. P. Davis, F. S. Bates, D. A. Hammer, and J. A. Burdick, Membrane stabilization of biodegradable polymersomes. Langmuir 25, 4429 (2009).
23. C. Sanson, C. Schatz, J. F. Le Meins, A. Brulet, A. Soum, and S. Lecommandoux, Biocompatible and biodegradable poly(trimethylene carbonate)-b-poly(L-glutamic acid) polymersomes: size control and stability. Langmuir 26, 2751 (2010).
24. J. P. Jain and N. Kumar, Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation. Eur. J. Pharm. Sci. 40, 456 (2010).
25. R. C. Hayward, A. S. Utada, N. Dan, and D. A. Weitz, Dewetting instability during the formation of polymersomes from block-copolymer-stabilized double emulsions. Langmuir 22, 4457 (2006).
26. T. Yang, Y. Wang, Z. Li, W. Dai, J. Yin, L. Liang, X. Ying, S. Zhou, J. Wang, X. Zhang, and Q. Zhang, Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine 8, 81 (2012).
27. M. R. Stratford and M. F. Dennis, Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography. J. Chromatogr. B. 721, 77 (1999).
28. I. G. Kirwan, Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin. Cancer. Res. 10, 1446 (2004).
29. D. Schmaljohann, Thermo-and pH-responsive polymers in drug delivery. Adv. Drug Delivery Rev. 58, 1655 (2006).
30. T. C. Chou and P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27 (1984).
31. T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621 (2006).
32. J. Guo, D. M. Clausen, J. H. Beumer, R. A. Parise, M. J. Egorin, K. Bravo-Altamirano, P. Wipf, E. R. Sharlow, Q. J. Wang, and J. L. Eiseman, In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts. Cancer Chemoth. Pharm. 71, 331 (2013).
33. W. Xu, I. A. Siddiqui, M. Nihal, S. Pilla, K. Rosenthal, H. Mukhtar, and S. Gong, Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 34, 5244 (2013).
34. Y. Li, Y. Lei, E. Wagner, C. Xie, W. Lu, J. Zhu, J. Shen, J. Wang, and M. Liu, Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells. Bioconjugate Chem. 24, 133 (2013).
35. Z. Wang and P. C. Ho, A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31, 7115 (2010).
36. Z. Wang, W. K. Chui, and P. C. Ho, Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm. Res. 28, 585 (2011).
37. W. Y. Ayen, K. Garkhal, and N. Kumar, Doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study. Mol. Pharma. 8, 466 (2011).
38. F. Ahmed, R. I. Pakunlu, A. Brannan, F. Bates, T. Minko, and D. E. Discher, Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J. Control. Release 116, 150 (2006).
39. P. P. Ghoroghchian, G. Li, D. H. Levine, K. P. Davis, F. S. Bates, D. A. Hammer, and M. J. Therien, Bioresorbable vesicles formed through spontaneous self-assembly of amphiphilic poly(ethylene oxide)-block-polycaprolactone. Macromolecules 39, 1673 (2006).
40. C. Sanson, C. Schatz, J. F. Le Meins, A. Soum, J. Thévenot, E. Garanger, and S. Lecommandoux, A simple method to achieve high doxorubicin loading in biodegradable polymersomes. J. Control Release 147, 428 (2010).
41. J. S. Lee, M. Ankone, E. Pieters, R. M. Schiffelers, W. E. Hennink, and J. Feijen, Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: Comparison with stealth liposomes. J. Control. Release 155, 282 (2011).
42. P. J. Photos, L. Bacakova, B. Discher, F. S. Bates, and D. E. Discher, Polymer vesicles in vivo: Correlations with PEG molecular weight. J. Control. Release 90, 323 (2003).
43. K. K. Upadhyay, A. N. Bhatt, E. Castro, A. K. Mishra, K. Chuttani, B. S. Dwarakanath, C. Schatz, J. F. Le Meins, A. Misra, and S. Lecommandoux, In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol. Biosci. 10, 503 (2010).
44. S. D. Li and L. Huang, Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharma. 5, 496 (2008).
45. A. L. Klibanov, K. Maruyama, V. P. Torchilin, and L. Huang, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. Febs. Lett. 268, 235 (1990).
46. L. Y. Qiu, L. Yan, L. Zhang, Y. M. Jin, and Q. H. Zhao, Folatemodified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery. Int. J. Pharm. 456, 315 (2013).